BEXSERO
Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)

Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)
BEXSERO is not indicated to treat or reduce the consequences of meningococcal meningitis (including meningitis, sepsis, and death) following the onset of invasive meningococcal disease.
BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains. Protection against IMD caused by other serogroups has not been studied. Therefore, protection against other serogroups should not be assumed with BEXSERO. As with any vaccine, BEXSERO may not protect all vaccine recipients.
This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.